Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
ATMARINOMED6
Thu, 19.12.2024
Marinomed Biotech AG
Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division
Required majority of shareholders vote in favour of the sale of the Carragelose business unit
Proceeds from the sale ensure implementation of the restructuring plan and commercialization of the Marinosolv platform
Dr. Karl Mahler elected to the Supervisory [ … ]
Tue, 17.12.2024
Marinomed Biotech AG
Marinomed Biotech AG: Requirements for successful completion of the restructuring proceedings achieved
Funds deposited for cash quota and to cover legal costs
European Investment Bank (EIB) agrees to standstill declaration
Implementation of the restructuring plan and the Company's sustainable continued existence are to be secured by the sale of [ … ]
Wed, 27.11.2024
Marinomed Biotech AG
Marinomed Biotech AG signs agreement for sale of Carragelose business to French Unither Pharmaceuticals
Marinomed to sell Carragelose business to Unither Pharmaceuticals, a leading contract development and manufacturing organization (CDMO) of medical devices and pharmaceutical products
Proceeds from sale of Carragelose business amounting to up t [ … ]
Tue, 12.11.2024
Marinomed Biotech AG
Marinomed Biotech AG publishes clinical data for decongestant Carragelose nasal spray in peer-reviewed International Journal of General Medicine
Marinomed’s nasal spray containing Carragelose and Sorbitol significantly improves breathing due to its decongestant effect in patients suffering from allergic rhinitis
Results of the clinical study show [ … ]
Tue, 08.10.2024
Marinomed Biotech AG
Marinomed Biotech AG publishes remarkable results showing alleviation of allergic eye inflammation in patients treated with Tacrolimus eye drops in peer-reviewed journal
Tacrosolv eye drops, a low-dose, aqueous Marinosolv-enabled formulation of Tacrolimus, are safe and effective in alleviating symptoms of allergic rhinoconjunctivitis
Data from ph [ … ]
Tue, 24.09.2024
Marinomed Biotech AG
Marinomed Biotech AG reports positive clinical results for unique Carragelose eye drops
Marinomeds new Carragelose eye drops improve dry eye-related symptoms in patients with mild to moderate dry eye syndrome by remarkable 54%
Product was well tolerated by patients and ocular surface disease index (OSDI) was significantly reduced
Eye drops hold [ … ]
Tue, 24.09.2024
Marinomed Biotech AG
Marinomed Biotech AG reports positive clinical results for unique Carragelose eye drops
Marinomeds new Carragelose eye drops improve dry eye-related symptoms in patients with mild to moderate dry eye syndrome by remarkable 54%
Product was well tolerated by patients and ocular surface disease index (OSDI) was significantly reduced
Eye drops hold [ … ]
Wed, 11.09.2024
Marinomed Biotech AG
Marinomed Biotech AG: First Carragelose products receive new Medical Device Regulation (MDR) certification
Two Carragelose nasal sprays have received declaration of conformity under the new medical device regulation - certificates for further products expected later in the year
Extensive clinical data for Carragelose facilitates challenging deman [ … ]
Tue, 20.08.2024
Marinomed Biotech AG
Marinomed Biotech AG reports preliminary financial figures for the first half of 2024
Revenues of EUR 2.5 million generated in the first half of 2024 (H1 2023: EUR 5.2 million); cash and cash equivalents as of 30.06.2024 at EUR 0.9 million (31.12.2023: EUR 2.6 million)
Court restructuring proceedings without self-administration opened on August 1 [ … ]
Wed, 14.08.2024
Marinomed Biotech AG
Marinomed Biotech AG aims for financial reorganization by restructuring proceedings without self-administration
Application for opening of restructuring proceedings
Funds necessary to secure liquidity could not be raised as planned
This step is intended to ensure the Company's continued existence in the long term in agreement with its creditors [ … ]